Cowden Syndrome: A Rare Hereditary Cancer Predisposition Disorder
Cowden syndrome is a rare autosomal dominant hereditary cancer syndrome caused by germline mutations in the PTEN tumor suppressor gene, characterized by multiple hamartomas affecting various organs and a markedly elevated lifetime risk of malignancies—particularly breast (77-85%), thyroid (21-38%), endometrial (19-28%), renal (15-34%), and colorectal (9-16%) cancers. 1
Genetic Basis and Classification
Cowden syndrome falls under the umbrella term PTEN Hamartoma Tumor Syndrome (PHTS), which encompasses several related conditions including Bannayan-Riley-Ruvalcaba syndrome, Adult Lhermitte-Duclos disease, Proteus-like syndrome, and autism spectrum disorders with macrocephaly 1, 2. The syndrome results from heterozygous pathogenic variants in the PTEN gene located on chromosome 10q23.31, with an estimated penetrance of approximately 80% 1.
The incidence is reported as 1 in 200,000, though this is likely underestimated due to diagnostic challenges 1.
Clinical Manifestations
Characteristic Features Present by the 20s
The hallmark clinical features include:
- Mucocutaneous lesions (present in 99% of patients): trichilemmomas (benign hair follicle tumors), papillomatous papules, palmoplantar keratoses, and oral papillomas 1
- Macrocephaly (head circumference >97th percentile): occurs in approximately 80% of individuals 1
- Two or more trichilemmomas are considered pathognomonic, though histologic confirmation is essential 1
Gastrointestinal Manifestations
Gastrointestinal polyps occur in 80-93% of PTEN mutation carriers, predominantly hamartomatous polyps and ganglioneuromas 1. Importantly, early-onset colorectal cancer (before age 50) occurs in 13% of patients 1.
Malignancy Risks
Women face the highest cancer burden:
- Breast cancer: 77-85% lifetime risk, average diagnosis age 38-46 years, often bilateral and multifocal 1
- Thyroid cancer: 21-38% lifetime risk (follicular or papillary), with 3-7% developing differentiated thyroid cancer before age 20 and the earliest reported case at age 7 1, 2, 3
- Endometrial cancer: 19-28% lifetime risk 1
Both sexes:
- Renal cell carcinoma: 15-34% lifetime risk 1
- Colorectal cancer: 9-16% lifetime risk 1
- Melanoma: 6% lifetime risk 1
The cumulative lifetime risk of developing any cancer is 85-89%, with women having a 2-fold greater cancer risk compared to men with PHTS 1.
Neurologic Manifestations
Adult Lhermitte-Duclos disease (dysplastic gangliocytoma of the cerebellum) has a 32% cumulative lifetime risk and is strongly associated with PTEN mutations 1. Brain tumors and vascular malformations can occur but risks are not well-defined 1.
Pediatric Presentations
In children, manifestations include:
- Macrocephaly with autism spectrum disorder or developmental delay
- Gastrointestinal polyps
- Intellectual disability
- Multinodular goiter or differentiated thyroid cancer (5% risk before age 20) 2, 3
Diagnostic Criteria for PTEN Testing
According to NCCN guidelines 1, PTEN genetic testing is warranted when patients meet specific combinations of criteria:
Pathognomonic Features (Any Single Criterion Warrants Testing):
- Clinical diagnosis of Cowden syndrome
- Bannayan-Riley-Ruvalcaba syndrome
- Adult Lhermitte-Duclos disease
- Two or more biopsy-proven trichilemmomas
- Known familial PTEN mutation
Major Criteria (Require Specific Combinations):
- Breast cancer
- Endometrial cancer (epithelial)
- Follicular thyroid cancer
- Gastrointestinal hamartomas (≥3 ganglioneuromas)
- Lhermitte-Duclos disease
- Macrocephaly (≥97th percentile: 58 cm females, 60 cm males)
- Macular pigmentation of glans penis
- Multiple mucocutaneous lesions (≥3 trichilemmomas, ≥3 palmoplantar keratotic pits, ≥3 mucocutaneous neuromas, or oral papillomas)
Testing threshold met by:
- Two or more major criteria with one being macrocephaly, OR
- Three major criteria without macrocephaly, OR
- One major and three minor criteria, OR
- Four minor criteria 1
Minor Criteria:
Autism spectrum disorder (without macrocephaly), colon cancer, esophageal glycogenic acanthosis (≥3), lipomas, intellectual disability, papillary thyroid cancer, thyroid structural lesions, renal cell carcinoma, single gastrointestinal hamartoma, testicular lipomatosis, vascular anomalies 1
Important Clinical Pitfalls
Ascertainment bias significantly inflates cancer risk estimates in older studies, as patients were often selected for PTEN testing based on cancer presence 1. The diagnostic criteria established in 1996 by the International Cowden Consortium have been repeatedly updated, and much older literature predates these standardized criteria 1.
Not all patients with clinical Cowden syndrome have detectable PTEN mutations—only 60-92% of clinically diagnosed patients test positive 1, 4. Conversely, some PTEN mutation carriers may not meet full clinical diagnostic criteria 2, 3.
Trichilemmomas require histologic confirmation as they cannot be reliably distinguished clinically from other mucocutaneous lesions 1.
Surveillance Implications
Given the 85-89% lifetime cancer risk, affected individuals require intensive multi-organ surveillance beginning in childhood for thyroid cancer and expanding to breast, endometrial, renal, and colorectal screening in adulthood 1, 2. The National Comprehensive Cancer Network provides regularly updated surveillance protocols specific to PHTS 1, 2.